Tarextumab: Phase Ib/II data

OncoMed said it will unblind the double-blind, U.S. Phase Ib/II ALPINE trial in 172 evaluable patients with previously untreated stage IV pancreatic cancer after a

Read the full 251 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE